The development of new therapies for heart failure has led to substantial increases in the cost of care for these patients. Cost-effectiveness analyses can help quantify the relationship between clinical outcomes and the economic implications of available therapies. In this Review, Rohde and colleagues critically appraise cost-effectiveness studies on key areas of heart failure pharmacologically and nonpharmacological treatment options, including medical devices and heart transplant.
- Luis E. Rohde
- Eduardo G. Bertoldi
- Carísi A. Polanczyk
